Ascletis receives FDA clearance to begin Phase III ASC30 programme
The Phase III programme includes two trials enrolling 4,600 participants with obesity or overweight in the US, Canada, and Europe.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance